selected scholarly activity
-
chapters
- Prevention of the Consequences of Diabetes – a Commentary. 266-272. 2010
- Dysglycemia and the Risk of Cardiovascular Events. 179-189. 2009
- Can We Change the Body Fat Distribution Phenotype? Lessons from PPAR gamma Agonists. 111-116. 2009
- Gestational diabetes. 393-402. 2006
- Glucose Abnormalities and Cardiovascular Disease: “Dysglycemia” as an Emerging Cardiovascular Risk Factor. 161-169. 2002
-
conferences
- Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial. European Journal of Heart Failure. 1805-1812. 2022
- ASSOCIATION BETWEEN BARIATRIC SURGERY AND ALL-CAUSE MORTALITY IN PATIENTS WITH DIABETES: A POPULATION-BASED MATCHED COHORT STUDY IN A UNIVERSAL HEALTHCARE SYSTEM Type 2 diabetes and metabolic surgery. Obesity Surgery. 58-58. 2022
- 1102-P: Identifying Blood Biomarkers for Type 2 Diabetes Subtyping: A Report from the ORIGIN Trial. Diabetes. 2022
- 1263-P: Adolescent Obesity and Incident Type 1 Diabetes in Young Adulthood. Diabetes. 2022
- 162-LB: Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome—The ELIXA Biomarker Study. Diabetes. 2022
- 725-P: Protein Biomarkers Associated with Dulaglutide and Cardiovascular Events in REWIND. Diabetes. 2022
- 731-P: Metabolite Biomarkers and Cardiovascular Events in REWIND: A Post Hoc Analysis. Diabetes. 2022
- Lixilan ONE CAN: Randomisierte Studie zum Vergleich eines täglichen vs. wöchentlichen Titrationsalgorithmus für den Wechsel von Basalinsulin zur Fixkombination iGlarLixi bei Typ-2-Diabetespatienten in Kanada. Diabetologie und Stoffwechsel. s28-s29. 2022
- PREDICTING DIABETES AND ITS COMPLICATIONS FROM NAILFOLD CAPILLAROSCOPY IMAGES USING DEEP LEARNING: A PILOT STUDY. Diabetes Technology and Therapeutics. A228-A228. 2022
- Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. Diabetologia. 206-215. 2022
- Impact of Sodium-Glucose Co-Transporter-2 Inhibition on the Efficacy and Safety of the Glucagon-like Peptide-1 Receptor Agonist Efpeglenatide in Type 2 Diabetes. Circulation. E584-E584. 2021
- Impact of Sodium-Glucose Co-Transporter-2 Inhibition on the Efficacy and Safety of the Glucagon-like Peptide-1 Receptor Agonist Efpeglenatide in Type 2 Diabetes. Circulation. E584-E584. 2021
- Gender differences in cardiovascular risk, treatment, and outcomes: a post-hoc analysis from the REWIND trial. Diabetologia. 4-5. 2021
- Remission of type 2 diabetes following a short-term intervention with insulin glargine and metformin/sitagliptin: results of the REMIT-sita randomised controlled trial. Diabetologia. 223-224. 2021
- Remission of type 2 diabetes following intensive treatment with insulin glargine/lixisenatide, metformin and lifestyle approaches: results of the REMIT-iGlarLixi trial. Diabetologia. 224-224. 2021
- 187-OR: Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes in the ACCORD Trial. Diabetes. 2021
- 677-P: Remission of Type 2 Diabetes following Intensive Treatment with Insulin Glargine, Lixisenatide, Metformin, and Lifestyle Approaches: Results of a Multicenter Randomized Controlled Trial. Diabetes. 2021
- 95-LB: LixilanONE CAN: Randomized Trial Comparing a Daily vs. Weekly Titration Algorithm for Switching from Basal Insulin to iGlarLixi Fixed-Ratio Combination in People with T2DM in Canada. Diabetes. 2021
- EASE OF USING IGLARLIXI PEN AFTER INSULIN GLARGINE GLA-100: RESULTS FROM PATIENT AND HEALTHCARE PROVIDER QUESTIONNAIRES FROM THE ONE CAN PEN SUB-STUDY. Diabetes Technology and Therapeutics. A190-A190. 2021
- Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial. Circulation. 2020
- Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis. European Heart Journal. 3350-3350. 2020
- Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial. European Heart Journal. 3353-3353. 2020
- The Effect of Diabetes Health Coaching on Glycemic Control and Quality of Life in Adults Living With Type 2 Diabetes: A Community-Based Randomized Controlled Trial. Canadian Journal of Diabetes. S2-S2. 2020
- Cardio protection with dulaglutide is not depending on baseline therapy with metformin: a subgroup analysis of the REWIND trial. Diabetologia. S282-S282. 2020
- Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis. Diabetologia. S282-S282. 2020
- Dulaglutide reduces HbA(1c) irrespective of antihyperglycaemic agents, duration of diabetes, BMI and weight loss: a post hoc analysis from the REWIND trial. Diabetologia. S288-S288. 2020
- Effect of dulaglutide on kidney function-related outcomes in type 2 diabetes: post hoc analysis from the REWIND trial. Diabetologia. S281-S281. 2020
- Effects of intensive risk factor management on cardiovascular autonomic neuropathy in type 2 diabetes: findings from the ACCORD clinical trial. Diabetologia. S93-S93. 2020
- Exploring potential mediators of the cardiovascular benefit of dulaglutide in REWIND. Diabetologia. S74-S74. 2020
- 130-OR: Effects of Intensive Risk Factor Management on Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: Findings from the ACCORD Trial. Diabetes. 2020
- 1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event. Diabetes. 2020
- 356-OR: Effect of Dulaglutide on Kidney Function–Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial. Diabetes. 2020
- 924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND. Diabetes. 2020
- 944-P: HbA1c Change Is Associated with Retinopathy Outcomes during GLP-1RA CVOT Follow-Up. Diabetes. 2020
- DULAGLUTIDE REDUCES HBA1C IRRESPECTIVE OF ANTIHYPERGLYCEMIC AGENTS, DURATION OF DIABETES, BMI AND WEIGHT LOSS: A POST HOC ANALYSIS FROM THE REWIND TRIAL. Journal of the American College of Cardiology. 1951-1951. 2020
- Influence of Genetic Ancestry on Human Serum Proteome. American Journal of Human Genetics. 303-314. 2020
- Are the Beneficial Cardiovascular Effects of Glucagon-Like Peptide 1 Receptor Agonists in Diabetic Patients Metabolically Mediated?. Circulation. E974-E975. 2019
- Angiotensin-converting enzyme and type 2 diabetes risk: a Mendelian randomisation study. Diabetologia. S108-S108. 2019
- Diabetes regression and remission following a short-term intensive metabolic intervention with insulin glargine, metformin and dapagliflozin. Diabetologia. S360-S361. 2019
- Novel biomarkers predicting renal decline in people with dysglycaemia in the ORIGIN trial. Diabetologia. S98-S98. 2019
- 1506-P: Breast Cancer as a Risk Factor for New Diabetes. Diabetes. 2019
- 240-LB: Angiotensin-Converting Enzyme and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes. 2019
- 254-OR: Novel Biomarkers Predicting Renal Dysfunction in People with Dysglycemia in the ORIGIN Trial. Diabetes. 2019
- DYSGLYCEMIA, EJECTION FRACTION, AND THE RISK OF HEART FAILURE OR CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology. 773-773. 2019
- TESTOSTERONE AND SEX HORMONE-BINDING GLOBULIN IN DYSGLYCEMIC WOMEN AT HIGH CARDIOVASCULAR RISK: A REPORT FROM THE OUTCOME REDUCTION WITH AN INITIAL GLARGINE INTERVENTION TRIAL. Journal of the American College of Cardiology. 1760-1760. 2019
- Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE). Diabetologia. S344-S344. 2018
- Effect of free testosterone levels on cardiovascular outcomes: a Mendelian randomization analysis. European Heart Journal. 1329-1330. 2018
- Neighborhood Walkability and Diabetes-Related Complications. Diabetes. 2018
- Testosterone Levels and Risk for Cardiovascular Events - A Report From the ORIGIN (Outcome Reduction With an Initial Glargine Intervention) Trial. Circulation. 2017
- Item reduction and validation of the Chinese version of Diabetes Quality-of-Life Measure (DQOL). Quality of Life Research. 124-125. 2017
- IGFBP-3 is a marker of impaired adipose tissue function and a novel causal mediator of type 2 diabetes risk: a report from the ORIGIN study. Diabetologia. S99-S99. 2017
- Novel biomarkers predicting heart failure hospitalisation in people with dysglycaemia in the ORIGIN trial. Diabetologia. S40-S40. 2017
- CHANGES IN THE INTRA-ABDOMINAL FAT DEPOTS AND ASSOCIATIONS WITH GLYCEMIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES UNDERGOING BARIATRIC SURGERY Type 2 diabetes and metabolic surgery. Obesity Surgery. 280-280. 2017
- Genetic Predictors of Cardiovascular Outcomes during Intensive Blood Pressure Control in ACCORD. Diabetes. A3-A3. 2017
- Novel Biomarkers Predicting Heart Failure Hospitalization in People with Dysglycemia in the ORIGIN Trial. Diabetes. A405-A405. 2017
- Statistical considerations for analyzing multiplex biomarker data from prospective studies. Trials. 2017
- Increases in natriuretic peptides precede heart failure hospitalization in patients with a recent coronary event and type 2 diabetes. European Journal of Heart Failure. 197-197. 2017
- Mendelian Randomization (MR) Predicts a Causal Role for Serum ACE, APOC-1, APOE, Clusterin, and GDF-15 in Alzheimer Disease (AD). Genetic Epidemiology. 626-627. 2016
- Changes in BNP prior to major cardiovascular events in patients with type 2 diabetes and a recent coronary event. European Heart Journal. 220-220. 2016
- Effects of lixisenatide on natriuretic peptides in patients with diabetes and acute coronary syndrome. Diabetologia. S515-S515. 2016
- Identification of blood CSF1 and CXCL12 as new causal mediators of coronary artery disease using Mendelian randomization in the ORIGIN trial. European Heart Journal. 458-458. 2016
- Novel biomarkers predicting a microvascular composite outcome in people with dysglycaemia in the ORIGIN trial. Diabetologia. S161-S161. 2016
- Performance of the validated ORIGIN cardiovascular biomarker panel in HOPE study participants with diabetes. Diabetologia. S31-S31. 2016
- BNP Enhances Predictive Models of Cardiovascular Outcomes in Patients with Type 2 Diabetes and a Recent Coronary Event. Diabetes. A112-A113. 2016
- Genetic Predictors of Cardiovascular Mortality during Intensive Glycemic Control in Type 2 Diabetes. Diabetes. A82-A82. 2016
- Novel Biomarkers Predicting a Microvascular Composite Outcome in People with Dysglycemia in the ORIGIN Trial. Diabetes. A388-A388. 2016
- Performance of the Validated ORIGIN Cardiovascular Biomarker Panel in HOPE Study Participants with Diabetes. Diabetes. A363-A363. 2016
- Predictors of Remission of Type 2 Diabetes following a Short-Term Intensive Metabolic Intervention. Diabetes. A437-A438. 2015
- Self-Perceived Distress and Diabetes Risk among Young Men. Diabetes. A406-A406. 2015
- Effects of Insulin Glargine on Left Ventricular Mass and Function in Patients With Dysglycemia. Circulation. 2014
- Outcome reduction with an initial glargine intervention and legacy effects (ORIGINALE). Diabetologia. S516-S516. 2014
- Clinical and Biochemical Markers of Nonprogression to Type 2 Diabetes Mellitus from a "Prediabetes" Stage. Diabetes. A365-A365. 2014
- Perinatal Exposure to the Selective Serotonin Reuptake Inhibitor Fluoxetine Results in Hepatic Lipid Accumulation and Inflammation. Endocrine Reviews. 2014
- Prevalence and Determinants of Peripheral Neuropathy and Nerve Dysfunction in a Population at High Risk for Type 2 Diabetes-The PROMISE Cohort. Diabetes. A30-A30. 2014
- Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal. 352-352. 2013
- Association of Differential White Blood Cell Count With Insulin Resistance and beta-Cell Dysfunction-The PROMISE Cohort. Diabetes. A406-A406. 2013
- Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial. Diabetes. A98-A98. 2013
- Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial. Diabetes. A72-A72. 2013
- Effect of Basal Insulin Glargine and Omega 3 FA on Cognitive Decline and Dementia in People With Dysglycemia. Diabetes. A308-A308. 2013
- Handgrip Strength Is Associated With Glomerular Filtration Rate in Patients With Diabetes Type 2. Diabetes. A393-A393. 2013
- Handgrip Strength Predicts Cardiovascular Mortality: A Subanalysis of the ORIGIN Trial. Diabetes. A367-A367. 2013
- The Association of Leg Length With Metabolic Abnormalities Underlying Type 2 Diabetes Mellitus: The PROMISE Cohort. Diabetes. A412-A412. 2013
- A new in vivo methodology for quantifying intramuscular adipose tissue (IMAT) in the lower leg of women to define the relationship with BMD, strength, physical function and lifestyle variables. Journal of Bone and Mineral Research. 2013
- 422 Accelerated Adipose Tissue Dysfunction and Cardiovascular Risk in Individuals of South Asian Ethnicity. Canadian Journal of Cardiology. S258-S258. 2012
- IS ACCELERATED ATHEROSCLEROSIS A MICROVASCULAR COMPLICATION OF DIABETES?. Canadian Journal of Cardiology. S95-S96. 2012
- Alanine Transaminase and Waist to Hip Ratio Predict Regression to Normoglycemia and AUC(glucose0-120 min) in Adult Patients With Prediabetes. Diabetes. A390-A390. 2012
- Changes in Adiposity Predict Changes in Serum 25(OH)D Over 3 Years of Follow-up: The PROspective Metabolism and Islet Cell Evaluation (PROMISE) Cohort Study. Diabetes. A359-A359. 2012
- Evaluating the Feasibility and Impact of an Internet-Based Lifestyle Modification Program in a Clinical Setting. Diabetes. A507-A507. 2012
- Fetal Exposure to the Selective Serotonin Reuptake Inhibitor Sertraline Results in Impaired Fetal Growth and Pancreatic Development in Wistar Rats. Reproductive Sciences. 119A-119A. 2012
- Microvascular effects of intensive blood pressure control and its relation to glycaemic control in the ACCORD blood pressure trial. Diabetologia. S23-S24. 2011
- Postnatal Reproductive Health Following Fetal and Neonatal Exposure to the Smoking Cessation Drug Bupropion. Journal of Developmental Origins of Health and Disease. S6-S6. 2011
- Alanine Aminotransferase and Progression of Insulin Resistance and Beta Cell Dysfunction. Diabetes. A361-A361. 2011
- Is Insulin Exposure Associated with Higher Risk of Cancer-Related Hospitalization or Death? Analysis of 5-Year Data from the ACCORD Trial. Diabetes. A99-A100. 2011
- Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit: The RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) Trial. Diabetes. A256-A256. 2011
- Prospective Association of Vitamin D with Beta-Cell Function and Glycemia. Diabetes. A89-A89. 2011
- Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial.. Journal of Clinical Oncology. 1504-1504. 2011
- Postnatal Metabolic Health Following Fetal and Neonatal Exposure to the Antidepressant Bupropion.. Reproductive Sciences. 211A-211A. 2011
- INVESTIGATING THE PRO-ATHEROGENIC POTENTIAL OF CHRONIC HYPERGLYCAEMIA: IS DIABETIC ATHEROSCLEROSIS A MICROVASCULAR COMPLICATION?. Canadian Journal of Cardiology. 119D-119D. 2010
- Evaluation of intra-stent neointima hyperplasia in the approach trial (assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history). European Heart Journal. 103-103. 2009
- Once-daily insulin glargine requires a significantly lower dose than insulin detemir twice daily to achieve good glycaemic control in patients with type 2 diabetes failing oral therapy. Diabetologia. S380-S380. 2009
- Prevalence & prognostic importance of micro-& macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme. European Heart Journal. 876-876. 2009
- Serial assessments of coronary remodeling from the approach trial (assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history). European Heart Journal. 298-298. 2009
- Association of Hematological Parameters with Insulin Sensitivity and beta-Cell Dysfunction in Non-Diabetic Subjects. Diabetes. A250-A250. 2009
- Cardiac Autonomic Dysfunction Prodicts Cardiovascular Mortality in the Action To Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes. A63-A63. 2009
- Effect of Rosiglitazone and Ramipril on beta-Cell Function in Subjects with Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose (IFG): The DREAM Trial. Diabetes. A255-A255. 2009
- Impact of Ramipril on Body Fat Compartments and Hepatic Fat in the DREAM Trial. Diabetes. A443-A443. 2009
- Impact of Rosiglitazone on Body Fat Compartments and Hepatic Fat in the DREAM Trial. Diabetes. A443-A443. 2009
- The Relationship between Dysglycemia Category and Cognitive Function: The ORIGIN Cognitive Sub-Study. Diabetes. A586-A586. 2009
- QL3 ESTIMATION OF UTILITY VALUES FOR DIABETESXD-RELATED COMPLICATIONS ON QUALITY OF LIFE FOR PATIENTS WITH TYPE-2 DIABETES IN ONTARIO, CANADA. Value in Health. A17-A17. 2009
- Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction. Journal of the American College of Cardiology. A467-A467. 2009
- Effect of Rosiglitazone on Left Ventricular Systolic and Diastolic Function and on NT-proBNP: Results of the Echocardiographic and Biomarker Substudy of the DREAM Trial. Circulation. S723-S723. 2008
- Digestive Disease Week and American Diabetes Association: Action to Control Cardiovascular Risk (ACCORD) Trial. P and T. 548. 2008
- Whole 24-hour continuous glucose monitoring profiles with insulin glargine or oral antidiabetic drug therapy in patients with type 2 diabetes mellitus. Diabetologia. S431-S431. 2008
- An oral glucose challenge induces endoplasmic reticulum stress in circulating blood cells and vascular tissue: A possible mechanism linking postprandial hyperglycemia to cardiovascular risk. Diabetes. A73-A73. 2008
- Diabetes management in Canada: Evidence of an ongoing care gap. Diabetes. A339-A339. 2008
- Echocardiographic epicardial fat predicts the metabolic syndrome. Diabetes. A481-A482. 2008
- Frailty grip is associated with glucose intolerance: Results from the epidemiological DREAM study population. Diabetes. A661-A661. 2008
- Management of vascular risk factors in a cohort of patients with type 2 diabetes mellitus (DM) in Canada: Significant gap between guidelines recommendations and current practice. Diabetes. A345-A346. 2008
- The relationship between baseline HbA1c levels and cognitive function in people with type 2 diabetes and other cardiovascular risk factors: The ACCORD-MIND study. Diabetes. A75-A75. 2008
- Whole 24-hour continuous glucose monitoring (CGM) profiles with insulin glargine or oral antidiabetic drug (OAD) therapy in patients with type 2 diabetes mellitus (T2DM). Diabetes. A118-A118. 2008
- Elevated in-hospital glucose level, and not known history of diabetes mellitus, predicts 30-day mortality following acute ST-elevation myocardial infarction. Circulation. 824-824. 2007
- Glucose levels predict incident cardiovascular events in a large international multiethnic cohort. Circulation. 835-835. 2007
- Obesity metrics and their associations with type 2 diabetes and glucose levels in a large international multi-ethnic cohort. Circulation. 318-319. 2007
- Glycemic control after angioplasty reduces stent restenosis in patients with diabetes: Results of the stent restenosis and metabolism (stream) study. Canadian Journal of Cardiology. 79C-80C. 2007
- The effect of rosiglitazone on peripheral insulin signaling and glucose utilization pathways following fetal and neonatal exposure to nicotine in rats. Diabetes. A681-A681. 2007
- A plea for intra-laboratory reference limits. Part 2. A bimodal retrospective concept for determining reference limits from intra-laboratory databases demonstrated by catalytic activity concentrations of enzymes. Clinical Chemistry and Laboratory Medicine. 1043-1057. 2007
- Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the heart outcomes prevention evaluation (HOPE) Study. Circulation. 871-871. 2006
- Fasting plasma glucose is an independent predictor of hospitalization for congestive heart failure in high-risk patients. Circulation. 530-530. 2006
- Diabetes status and fasting plasma glucose are independent determinants of cognitive status in people at high risk for cardiovascular disease. Diabetologia. 76-76. 2006
- Fasting glucose as a predictor of cardiovascular events in high-risk patients. European Heart Journal. 171-171. 2006
- Fasting plasma glucose and new onset of diabetes type 2 in high-risk patients. European Heart Journal. 520-520. 2006
- A systematic review and meta-analysis of hypoglycemia and cardiovascular events: A comparison of glyburide with other secretagogues and with insulin. Diabetes. A147-A147. 2006
- Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diabetes. A525-A525. 2006
- PDB57 TREATMENT SATISFACTION AND QUALITY OF LIFE WITH AN EARLY INSULINIZATION STRATEGYWITH INSULIN GLARGINE COMPARED TO AN ADJUSTED ORAL THERAPY IN THE MANAGEMENT OF TYPE-2 DIABETES: THE CANADIAN INSIGHT STUDY. Value in Health. A172-A172. 2005
- Prevention of diabetes in schizophrenia: A review of the scope and limitations. Schizophrenia Bulletin. 553-554. 2005
- A Randomized trial of early glargine use to achieve optimal Alc levels in insulin naive people with type 2 diabetes. Diabetes. A67-A68. 2005
- Cognitive decline in diabetes - A systematic overview and meta-analysis of observational studies. Diabetes. A40-A41. 2005
- Efficacy and safety of glargine insulin in primary care. Diabetologia. A311-A312. 2005
- Glucose control during early insulinization with glargine as assessed by the continuous glucose monitoring system (CGMS). Diabetologia. A309-A309. 2005
- Does Substitution of T4 with T3 Plus T4 for T4 Replacement Improve Depressive Symptoms in Patients with Hypothyroidism?. Annals of the New York Academy of Sciences. 287-288. 2004
- Thyroid function screening following radiation therapy for cancers of the head and neck: A survey of Canadian practice patterns. Radiotherapy and Oncology. S48-S48. 2004
- Design and baseline characteristics of the DREAM (diabetes REduction assessment with ramipril and rosiglitazone medication) trial. Diabetes. A483-A483. 2004
- Glucose & incident CVD in diabetic & nondiabetic patients on dialysis: Data from the GARRD study. Diabetes. A174-A174. 2004
- 810-1 Impact of the angiotensin-receptor blocker candesartan in preventing diabetes in patients with heart failure. Journal of the American College of Cardiology. A473-A473. 2004
- Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients. Journal of the American College of Cardiology. 291-291. 2002
- Impact of abdominal obesity on the occurrence of diabetes in subjects with ischemic cardiovascular disease. Circulation. 833-833. 2001
- Meal-based repaglinide therapy in type 2 diabetes can be titrated using either preprandial or postprandial blood glucose to maximize glycemic control. Diabetes. A114-A114. 2001
- Metabolic and hematological effects of ramipril in the HOPE trial. Circulation. 408-408. 2000
- Renal insufficiency as a predictor of cardiovascular outcomes and impact of ramipril: The HOPE study. Circulation. 655-655. 2000
- Differences in cardiovascular disease between ethnic groups are not explained by conventional risk factors or atherosclerosis. The study of health assessment and risk in ethnic groups (SHARE). Journal of the American College of Cardiology. 283A-284A. 2000
- Ramipril prevents cardiovascular events in high risk diabetic participants: Results of the HOPE study. Journal of the American College of Cardiology. 301A-301A. 2000
- Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS registry. Circulation. 640-640. 1999
- The efficacy and safety of acarbose in the treatment of type 2 diabetes mellitus in elderly patients.. Diabetologia. A223-A223. 1999
- Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Canadian Journal of Physiology and Pharmacology. 118-123. 1999
- Stress hyperglycemia and prognosis of myocardial infarction in nondiabetic and diabetic patients: a systematic overview. Diabetes. A373-A374. 1999
- Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Diabetes. A374-A374. 1999
- Albuminuria is highly prevalent and predicts cardiovascular events in high risk diabetic and nondiabetic patients. Circulation. 1245-1245. 1997
- A one day continuing medical education workshop improves primary care physicians' attitude, knowledge and self-reported practice patterns regarding diabetes.. Diabetes. 520-520. 1997
- Hydroxychloroquine improves glycemic control in NIDDM.. Diabetes. 642-642. 1997
- Continuous relationship of glucose with cardiovascular events in non diabetic subjects: A meta regression analysis of 18 studies in 88,000 individuals.. Circulation. 1245-1245. 1996
- Diabetes is an independent risk factor for increased left ventricular mass. Circulation. 2935-2935. 1996
- MICROALBUMINURIA AND MORTALITY IN NIDDM - A SYSTEMATIC OVERVIEW OF THE LITERATURE. Diabetes. A124-A124. 1995
- SEPARATE INDUCTION OF MHC AND THYROID MICROSOMAL ANTIGEN (MCAG) EXPRESSION ON THYROID-CELL MONOLAYERS - ENHANCEMENT OF LECTIN-INDUCED MCAG EXPRESSION BY INTERFERON-GAMMA. Annales d'Endocrinologie. 119-119. 1987
- NUCLEAR AND CYTOPLASMIC RNA-PROTEIN COMPLEXES FROM INFLUENZA-VIRUS INFECTED-CELLS. Journal of Cell Biology. A112-A112. 1976
-
journal articles
- Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial.. Diabetes, Obesity and Metabolism. 26:6080-6084. 2024
- Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.. Diabetes, Obesity and Metabolism. 26:5600-5608. 2024
- The Effects of Diabetes on Gas Transfer Capacity, Lung Volumes, Muscle Strength, and Cardio-pulmonary Responses During Exercise.. Lung. 202:767-774. 2024
- Role of the liver in the sustained normalisation of A1c over 2 years following short-term insulin therapy in early type 2 diabetes.. Diabetes, Obesity and Metabolism. 2024
- Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.. Circulation. 150:1781-1790. 2024
- Overweight and obesity among Israeli adolescents and the risk for serious morbidity in early young adulthood: a nationwide retrospective cohort study.. The Lancet Diabetes and Endocrinology. S2213-8587(24)00287-0. 2024
- A Glycemic Threshold Above Which the Improvement of β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Early Type 2 Diabetes: The Reversal of Glucotoxicity.. Diabetes Care. 47:2017-2023. 2024
- Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction.. European Heart Journal. ehae533. 2024
- Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches.. Trials. 25:644. 2024
- Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial.. Cardiovascular Diabetology. 23:352. 2024
- Relationships between ankle blood pressure indices and major adverse cardiovascular events in people with and without type 2 diabetes.. Cardiovascular Diabetology. 23:325. 2024
- Cognitive function in adolescence and the risk of early-onset stroke. Journal of Epidemiology and Community Health. 78:570-577. 2024
- Call for effective therapies for preventing dementia in people with type 2 diabetes. The Lancet Diabetes and Endocrinology. 12:510-513. 2024
-
Determinants of serious health
outcome‐free status inmiddle‐aged and older people with dysglycaemia: Exploratory analysis of theORIGIN trial. Diabetes, Obesity and Metabolism. 26:3272-3280. 2024 - Development and first‐stage validation of a digital version of the Digit Symbol Substitution test for use in assessing cognitive function in older people with diabetes. Diabetes, Obesity and Metabolism. 26:3299-3305. 2024
- ASCEND-Eye. Ophthalmology (Rochester, Minn.). 131:771-779. 2024
- Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study. European Heart Journal. 45:1738-1749. 2024
- ASCEND-Eye. Ophthalmology (Rochester, Minn.). 131:526-533. 2024
- How clinically relevant is statin-induced diabetes?. The Lancet Diabetes and Endocrinology. 12:286-287. 2024
- Contemporary Clinical Perspectives on Targeting Remission of Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism (JCEM). 109:1179-1188. 2024
- Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial. Diabetes, Obesity and Metabolism. 26:1216-1223. 2024
-
Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the
ORIGIN trial. Diabetes, Obesity and Metabolism. 26:1180-1187. 2024 - Non-coronary arterial outcomes in people with type 1 diabetes mellitus: a Swedish retrospective cohort study. The Lancet Regional Health - Europe. 39:100852-100852. 2024
- Non-coronary peripheral arterial complications in people with type 2 diabetes: a Swedish retrospective cohort study. The Lancet Regional Health - Europe. 39:100888-100888. 2024
- Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. 627:347-357. 2024
- Impact of COVID-19 Lockdown on Occurrence of Acute Complications of Type 1 and Type 2 Diabetes and Overall Glycemic Management. Canadian Journal of Diabetes. 48:120-124. 2024
- Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants. The Lancet Diabetes and Endocrinology. 12:107-118. 2024
- Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial. Journal of Diabetes. 16:e13473. 2024
- Vaspin: A Novel Biomarker Linking Gluteofemoral Body Fat and Type 2 Diabetes Risk. Diabetes Care. 47:259-266. 2024
- The association of red and processed meat with gestational diabetes mellitus: Results from 2 Canadian birth cohort studies. PLoS ONE. 19:e0302208-e0302208. 2024
- Visit-to-visit variability in multiple biological measurements and cognitive performance and risk of cardiovascular disease: A cohort study. Cerebral Circulation - Cognition and Behavior. 6:100223-100223. 2024
- Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial. Scandinavian Cardiovascular Journal. 57:2166101. 2023
- Cognitive performance following stroke, transient ischaemic attack, myocardial infarction, and hospitalisation: an individual participant data meta-analysis of six randomised controlled trials. The Lancet Healthy Longevity. 4:e665-e674. 2023
- Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia. Diabetes Research and Clinical Practice. 206:111010-111010. 2023
- Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia - Experiences from the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. European Heart Journal. 44:ehad655.926. 2023
- High BMI and the risk for incident type 1 Diabetes Mellitus: a systematic review and meta-analysis of aggregated cohort studies. Cardiovascular Diabetology. 22:300. 2023
- Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial. Diabetes, Obesity and Metabolism. 25:3347-3355. 2023
- IDENTIFICATION OF PAM AS NOVEL MONOGENIC DIABETES GENE. Canadian Journal of Diabetes. 47:S169-S170. 2023
- IDENTIFICATION OF PAM AS NOVEL MONOGENIC DIABETES GENE. Canadian Journal of Cardiology. 39:S205-S206. 2023
- Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment. European Heart Journal Open. 3:oead089. 2023
- Relationship between remnant cholesterol and risk of heart failure in participants with diabetes mellitus. European Heart Journal - Quality of Care and Clinical Outcomes. 9:537-545. 2023
- Relationship between remnant cholesterol and risk of heart failure in participants with diabetes mellitus: Reply. European Heart Journal - Quality of Care and Clinical Outcomes. 9:547-547. 2023
- Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis. Diabetes Care. 46:1524-1530. 2023
- Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes. Nature Communications. 14:4514. 2023
- Diet, cardiovascular disease, and mortality in 80 countries. European Heart Journal. 44:2560-2579. 2023
- GDF15 promotes weight loss by enhancing energy expenditure in muscle. Nature. 619:143-150. 2023
- Biomarkers Associated With Severe COVID-19 Among Populations With High Cardiometabolic Risk. JAMA network open. 6:e2325914-e2325914. 2023
- The Data Monitoring Committee: A Collective or a Collection?. Therapeutic Innovation and Regulatory Science. 57:653-655. 2023
- 221-LB: Identification of PAM as Novel Monogenic Diabetes Gene. Diabetes. 72. 2023
- Association of Intima‐Media Thickness Measured at the Common Carotid Artery With Incident Carotid Plaque: Individual Participant Data Meta‐Analysis of 20 Prospective Studies. Journal of the American Heart Association. 12:e027657. 2023
- Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study. Circulation. 147:1872-1886. 2023
- Identifying blood biomarkers for type 2 diabetes subtyping: a report from the ORIGIN trial. Diabetologia. 66:1045-1051. 2023
- A culturally tailored personaliseD nutrition intErvention in South ASIan women at risk of Gestational Diabetes Mellitus (DESI-GDM): a randomised controlled trial protocol. BMJ Open. 13:e072353-e072353. 2023
- Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis. Diabetes Care. 46:1046-1051. 2023
- Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study. The Lancet Diabetes and Endocrinology. 11:333-344. 2023
-
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The
ELIXA trial. Diabetes, Obesity and Metabolism. 25:1125-1129. 2023 - Patient Perspectives on the Ambulatory Glucose Profile Report for Type 1 Diabetes Management in Adults: A National Online Survey. Canadian Journal of Diabetes. 47:243-249.e2. 2023
- Thyroid Dysfunction and Cardiovascular Events in Patients With Dysglycemia. Canadian Journal of Diabetes. 47:257-262. 2023
- Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. Circulation. 147:1004-1013. 2023
- General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial. Cardiovascular Diabetology. 22:52. 2023
- Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes Therapy. 14:377-386. 2023
- Nailfold capillaroscopy and deep learning in diabetes. Journal of Diabetes. 15:145-151. 2023
- World-wide variations in tests of cognition and activities of daily living in participants of six international randomized controlled trials. Cerebral Circulation - Cognition and Behavior. 5:100176-100176. 2023
- Are U‐shaped relationships between risk factors and outcomes artifactual?. Journal of Diabetes. 14:815-821. 2022
- Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status. The Lancet Diabetes and Endocrinology. 10:831-832. 2022
- Identifying Blood Biomarkers for Type 2 Diabetes Subtyping: A Report From the ORIGIN Trial. Canadian Journal of Diabetes. 46:S5-S5. 2022
- Novel Combination of Continuous Glucose Monitoring Metrics to Predict HbA1c in Type 2 Diabetes. Canadian Journal of Diabetes. 46:S14-S14. 2022
- RF28 | PSUN302 Obesity at Late Adolescence and Incident Type 1 Diabetes in Young Adulthood. Journal of the Endocrine Society. 6:A429-A430. 2022
-
Reply to the letter regarding the article ‘Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a
post‐hoc analysis from theREWIND randomized trial’. European Journal of Heart Failure. 24:2207-2208. 2022 -
Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to
iGlarLixi in theLixiLan ONE CAN randomized trial. Diabetes, Obesity and Metabolism. 24:1998-2007. 2022 - Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis. Diabetes Care. 45:e146-e147. 2022
- Optimizing Health Coaching for Patients With Type 2 Diabetes Using Machine Learning: Model Development and Validation Study. JMIR Formative Research. 6:e37838-e37838. 2022
- Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation. Canadian Journal of Cardiology. 38:1434-1441. 2022
-
Efficacy and safety outcomes of dulaglutide by baseline
HbA1c : A post hoc analysis of theREWIND trial. Diabetes, Obesity and Metabolism. 24:1753-1761. 2022 - Obesity in late adolescence and incident type 1 diabetes in young adulthood. Diabetologia. 65:1473-1482. 2022
- Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. Diabetes Care. 45:2152-2155. 2022
- A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes. Cardiovascular Diabetology. 21:158. 2022
- Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. European Journal of Preventive Cardiology (EJPC). 29:1334-1342. 2022
- Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. Journal of Clinical Endocrinology and Metabolism (JCEM). 107:e3448-e3454. 2022
- Response by Lam and Gerstein to Letter Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial”. Circulation. 146:e7. 2022
- Glucose Intolerance in Pregnancy and Offspring Obesity in Late Adolescence. Diabetes. 45:1540-1548. 2022
- Cushing Syndrome Secondary to Ectopic ACTH Production in Pregnancy: A Case Report. Annals of Internal Medicine: Clinical Cases. 1. 2022
- Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684–691. Diabetes Care. 45:e111-e112. 2022
- 1276-P: Transancestral Genomic Analysis Links Dysregulation of Valine Metabolism to the Development of Heart Failure in Type 2 Diabetes. Diabetes. 71. 2022
- 190-LB: Vaspin—A Novel Predictor of Type 2 Diabetes Risk. Diabetes. 71. 2022
- Biomarkers of Prevalent and Incident Cognitive Dysfunction in People with Dysglycemia: Data from the ORIGIN Trial. Journal of Alzheimer's Disease. 87:1143-1150. 2022
- Shouldn’t Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?. Circulation. 145:1642-1644. 2022
- Author Correction: Identification of genetic effects underlying type 2 diabetes in South Asian and European populations. Communications Biology. 5:441. 2022
- Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nature Genetics. 54:560-572. 2022
- Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. Journal of the American Heart Association. 11:e021327. 2022
- Identification of genetic effects underlying type 2 diabetes in South Asian and European populations. Communications Biology. 5:329. 2022
-
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the
REWIND randomized trial. Diabetes, Obesity and Metabolism. 24:704-712. 2022 - Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care. 45:684-691. 2022
- Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabetologia. 39:e14669. 2022
- Economic Analysis of a Diabetes Health Coaching Intervention for Adults Living With Type 2 Diabetes: A Single-Centre Evaluation From a Community-Based Randomized Controlled Trial. Canadian Journal of Diabetes. 46:165-170. 2022
- HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial. Diabetes Care. 45:547-554. 2022
- Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. 145:565-574. 2022
- Myopia and Early-Onset Type 2 Diabetes: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism (JCEM). 107:e663-e671. 2022
- Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 16:102382-102382. 2022
- Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism (JCEM). 107:1-9. 2022
- Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. Diabetes Care. 45:178-185. 2022
- Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovascular Diabetology. 20:194. 2021
- Insulin Therapy: The Discovery That Shaped a Century. Canadian Journal of Diabetes. 45:798-803. 2021
- Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. New England Journal of Medicine. 385:2105-2107. 2021
- Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents. Journal of Clinical Endocrinology and Metabolism (JCEM). 106:e5043-e5053. 2021
- Adolescent cognitive function and incident early-onset type 2 diabetes. EClinicalMedicine. 41:101138-101138. 2021
- Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia. 64:2359-2366. 2021
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The Lancet Diabetes and Endocrinology. 9:653-662. 2021
- Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care. 44:2438-2444. 2021
- Effect of Diabetes Health Coaching on Glycemic Control and Quality of Life in Adults Living With Type 2 Diabetes: A Community-Based, Randomized, Controlled Trial. Canadian Journal of Diabetes. 45:594-600. 2021
- Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters. Diabetes Care. 44:2212-2215. 2021
- SODIUM-GLUCOSE CO-TRANSPORTER INHIBITORS AND ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Canadian Journal of Cardiology. 37:S44-S45. 2021
- Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association. 10:e022222. 2021
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. New England Journal of Medicine. 385:896-907. 2021
- Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood. Journal of Clinical Endocrinology and Metabolism (JCEM). 106:e3426-e3435. 2021
- Erectile dysfunction in men with type 2 diabetes treated with dulaglutide: an explanatory analysis of the REWIND placebo-controlled randomised controlled trial (vol 9, pg 484, 2021). The Lancet Diabetes and Endocrinology. 9:E3-E3. 2021
- Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. The Lancet Diabetes and Endocrinology. 9:484-490. 2021
-
Short‐term intensive insulin as induction and maintenance therapy for the preservation of beta‐cell function in early type 2 diabetes (
RESET‐IT Main ): A 2‐year randomized controlled trial. Diabetes, Obesity and Metabolism. 23:1926-1935. 2021 - Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal. 42:2565-2573. 2021
- NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia – A brief report from the ORIGIN trial. Journal of Diabetes and its Complications. 35:107928-107928. 2021
- Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. JAMA Internal Medicine. 181:631-631. 2021
- Creating Composite Indices From Continuous Variables for Research: The Geometric Mean. Diabetes Care. 44:e85-e86. 2021
- Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. Journal of Clinical Endocrinology and Metabolism (JCEM). 106:1345-1351. 2021
- Association Between Bariatric Surgery and Major Adverse Diabetes Outcomes in Patients With Diabetes and Obesity. JAMA network open. 4:e216820-e216820. 2021
- Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents. Journal of Clinical Endocrinology and Metabolism (JCEM). 106:e978-e987. 2021
- The Relationship Between Glucose Control and Cognitive Function in People With Diabetes After a Lacunar Stroke. Journal of Clinical Endocrinology and Metabolism (JCEM). 106:1521-1528. 2021
- Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial. Diabetes and Vascular Disease Research. 18:147916412110024-147916412110024. 2021
-
Design and baseline characteristics of the
AMPLITUDE‐O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist. Diabetes, Obesity and Metabolism. 23:318-323. 2021 - Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study. Journal of Clinical Endocrinology and Metabolism (JCEM). 106:e891-e898. 2021
- Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. Diabetes Care. 44:e6-e8. 2021
- Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. Journal of Clinical Endocrinology and Metabolism (JCEM). 106:e34-e44. 2021
- HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care. 44:290-296. 2021
- Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. Diabetes Care. 44:164-173. 2021
- Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. Cardiovascular Diabetology. 19:175. 2020
- Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. Diabetes Care. 43:3094-3101. 2020
- Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovascular Diabetology. 19:199. 2020
- Abstract 15586: Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial. Circulation. 142. 2020
- The obesity paradigm in cardiovascular disease: the need for differentiated weight management. European Heart Journal. 41:3965-3965. 2020
- Effects of lifelong testosterone exposure on health and disease using Mendelian randomization. eLife. 9:e58914. 2020
- 90 - Evaluating the Risk of Malignancy (ROM) in Thyroid Nodules With Bethesda Category III and IV at St. Joseph’s Hospital, Hamilton Compared to the Malignancy Rates Reported in the Bethesda System. Canadian Journal of Diabetes. 44:S34-S34. 2020
- Correction to Lancet Neurol 2020; 19: 582–90. Lancet Neurology. 19:e9-e9. 2020
- Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial. Journal of the American Society of Nephrology. 31:348-348. 2020
- Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. Diabetes Care. 43:2242-2247. 2020
- Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation. 142:621-642. 2020
- Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin. Journal of Clinical Endocrinology and Metabolism (JCEM). 105:2532-2540. 2020
- Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. European Heart Journal. 41:2668-2677. 2020
- Adolescent Obesity and Early-Onset Type 2 Diabetes. Diabetes Care. 43:1487-1495. 2020
- Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurology. 19:582-590. 2020
- Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. European Journal of Heart Failure. 22:1133-1143. 2020
- Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials. The Lancet Diabetes and Endocrinology. 8:557-558. 2020
- MON-636 The Relationship Between Glucose Control & Cognitive Function in People with Diabetes After a Lacunar Stroke. Journal of the Endocrine Society. 4:mon-636. 2020
- OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind. Journal of the Endocrine Society. 4:or30-or06. 2020
- Person-Centered, Outcomes-Driven Treatment: A New Paradigm for Type 2 Diabetes in Primary Care. ADA Clinical Compendia. 2020:1-28. 2020
- PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. Diabetes. 69:771-783. 2020
- ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes Care. 43:835-842. 2020
- Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. Circulation. 141:843-862. 2020
- Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors. Canadian Journal of Diabetes. 44:184-191. 2020
- Are large simple trials for dementia prevention possible?. Age and Ageing. 49:154-160. 2020
- Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154 000 Individuals. Journal of the American Heart Association. 9:e014686. 2020
- Dulaglutide slows kidney disease in type 2 diabetes − Author's reply. The Lancet. 395:559-560. 2020
- Identification of Circulating Proteins Associated With Blood Pressure Using Mendelian Randomization. Circulation. Genomic and precision medicine. 13:e002605. 2020
- Novel Biomarkers for Change in Renal Function in People With Dysglycemia. Diabetes Care. 43:433-439. 2020
- The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. The Lancet Diabetes and Endocrinology. 8:106-114. 2020
- Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood. Diabetes Care. 43:145-151. 2020
- Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nature Metabolism. 1:1202-1208. 2019
- 22 - Remission and Regression Following a Short-Term Intensive Metabolic Intervention With Insulin Glargine, Metformin and Dapagliflozin: The REMIT-DAPA Trial. Canadian Journal of Diabetes. 43:S9-S9. 2019
- The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes. Canadian Journal of Diabetes. 43:477-482. 2019
- Novel Drug Targets for Ischemic Stroke Identified Through Mendelian Randomization Analysis of the Blood Proteome. Circulation. 140:819-830. 2019
- Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk. Diabetes Care. 42:1800-1808. 2019
- Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. Endocrinologia, Diabetes y Nutricion. 66:467-468. 2019
- Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. Endocrinologia, Diabetes y Nutricion. 66:467-468. 2019
- The importance of randomised vs non-randomised trials – Authors' reply. The Lancet. 394:635-635. 2019
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 394:121-130. 2019
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet. 394:131-138. 2019
- The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study. Diabetes Care. 42:1159-1161. 2019
- Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. Trends in Molecular Medicine. 25:640-655. 2019
- Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Diabetes Care. 42:1136-1146. 2019
- Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. Diabetes, Obesity and Metabolism. 21:1502-1505. 2019
- Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes, Obesity and Metabolism. 21:1299-1304. 2019
- Dysglycemia and the Density of the Coronary Vasa Vasorum. Diabetes Care. 42:980-982. 2019
- Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial. European Journal of Preventive Cardiology (EJPC). 26:847-854. 2019
- A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease. Clinical Chemistry. 65:427-436. 2019
- The association of basal insulin treatment versus standard care with outcomes in anti‐GAD positive and negative subjects: A post‐hoc analysis of the ORIGIN trial. Diabetes, Obesity and Metabolism. 21:429-433. 2019
- Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. Diabetes Care. 42:142-147. 2019
- Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care. The Lancet Diabetes and Endocrinology. 7:4-5. 2019
- Real-world studies no substitute for RCTs in establishing efficacy. The Lancet. 393:210-211. 2019
- Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. Journal of Diabetes Research. 2018:1-9. 2018
- Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood. Cardiovascular Diabetology. 17:154. 2018
- Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL). Health and Quality of Life Outcomes. 16:78. 2018
- Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. Diabetes Care. 41:2404-2413. 2018
- Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community‐based survey in China. Diabetes/Metabolism Research and Reviews. 34:e3053. 2018
- Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study. The Lancet Diabetes and Endocrinology. 6:790-797. 2018
- Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. The Lancet Diabetes and Endocrinology. 6:798-808. 2018
- Do sulphonylureas still have a place in clinical practice?. The Lancet Diabetes and Endocrinology. 6:821-832. 2018
- Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer. Diabetes/Metabolism Research and Reviews. 34:e3018. 2018
- P6345Effect of free testosterone levels on cardiovascular outcomes: a Mendelian randomization analysis. European Heart Journal. 39:ehy566.p6345. 2018
- Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. Journal of the American College of Cardiology. 72:300-310. 2018
- A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. Diabetes Care. 41:1121-1124. 2018
- In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events. ACP journal club. 168:JC53-JC53. 2018
- Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal. 199:170-175. 2018
- The Genetic Link Between Diabetes and Atherosclerosis. Canadian Journal of Cardiology. 34:565-574. 2018
- Blood HER2 and Uromodulin as Causal Mediators of CKD. Journal of the American Society of Nephrology. 29:1326-1335. 2018
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. JAMA cardiology. 3:225-225. 2018
- Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America. 47:97-116. 2018
-
Insulin resistance and cardiovascular outcomes in the
ORIGIN trial. Diabetes, Obesity and Metabolism. 20:564-570. 2018 - Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis.. Annals of Clinical Psychiatry. 30:38-50. 2018
- Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. Diabetes Care. 41:348-355. 2018
- Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. Circulation. 137:88-90. 2018
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum. Diabetes Care. 41:14-31. 2018
-
Design and baseline characteristics of participants in the
R esearching cardiovascularE vents with aW eeklyIN cretin inD iabetes (REWIND ) trial on the cardiovascular effects of dulaglutide. Diabetes, Obesity and Metabolism. 20:42-49. 2018 - Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. American Journal of Medicine. 130:1465.e27-1465.e39. 2017
- Maturation of CGM and Glycemic Measurements Beyond HbA1c—A Turning Point in Research and Clinical Decisions. Diabetes Care. 40:1611-1613. 2017
- Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. American Journal of Human Genetics. 101:925-938. 2017
- Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Journal of the American Heart Association. 6:e004743. 2017
- Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes and Endocrinology. 5:877-886. 2017
- Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Circulation. 136:1560-1562. 2017
- Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. Diabetes Research and Clinical Practice. 132:137-143. 2017
- Optimizing the methodology for measuring supraclavicular skin temperature using infrared thermography; implications for measuring brown adipose tissue activity in humans. Scientific Reports. 7:11934. 2017
- The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident CVD in People With Diabetes: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study. Journal of Clinical Endocrinology and Metabolism (JCEM). 102:3218-3225. 2017
- Causes and consequences of gestational diabetes in South Asians living in Canada: results from a prospective cohort study. CMAJ open. 5:E604-E611. 2017
- Microvascular outcomes in type 2 diabetes – Authors' reply. The Lancet Diabetes and Endocrinology. 5:580-580. 2017
- Systematic review: Can non-mydriatic cameras accurately detect diabetic retinopathy?. Diabetes Research and Clinical Practice. 129:154-159. 2017
- The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial. Diabetes and Vascular Disease Research. 14:345-352. 2017
- Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People. Journal of Clinical Endocrinology and Metabolism (JCEM). 102:2251-2257. 2017
- Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. The Lancet Diabetes and Endocrinology. 5:431-437. 2017
- Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study. Scientific Reports. 7:1629. 2017
- Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism (JCEM). 102:1596-1605. 2017
- Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA cardiology. 2:370-370. 2017
- Growth Differentiation Factor 15 as a Novel Biomarker for Metformin. Diabetes Care. 40:280-283. 2017
- Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201. Diabetes Care. 40:e23-e24. 2017
- ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. Diabetologia. 60:69-80. 2017
- Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND). Trials. 17:286. 2016
- Drugs in diabetes in 2016, changes in endocrinology in 2015. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke. Polskie Archiwum Medycyny Wewnetrznej. 126:907-908. 2016
- BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide Cohort of 2.3 Million Adolescents. Diabetes Care. 39:1996-2003. 2016
- Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. Diabetes Care. 39:1915-1924. 2016
- Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke. Polskie Archiwum Medycyny Wewnetrznej. 126:803-805. 2016
- Cardiometabolic Health in Adults Born Premature With Extremely Low Birth Weight. Pediatrics. 138:e20160515. 2016
- The Prevalence of Undiagnosed Type 2 Diabetes On The General Medicine Ward. Canadian Journal of Diabetes. 40:S49-S50. 2016
- Toward Fairness in Data Sharing. New England Journal of Medicine. 375:405-407. 2016
- Longitudinal relationships between glycemic status and body mass index in a multiethnic study: evidence from observational and genetic epidemiology. Scientific Reports. 6:30744. 2016
- Making a Difference With Diabetes Research and Care. Diabetes Care. 39:1309-1310. 2016
- Numbers can save lives: Janice Pogue (1962–2016). Clinical Trials. 13:464-465. 2016
- Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care. 39:1089-1100. 2016
- Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care. 39:1186-1201. 2016
- Self-Perceived Emotional Distress and Diabetes Risk Among Young Men. American Journal of Preventive Medicine. 50:737-745. 2016
- Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care. 39:709-716. 2016
- Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care. 39:701-708. 2016
- Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. Diabetes Care. 39:780-787. 2016
- Sleep quality and risk of diabetes and coronary artery disease among young men. Acta Diabetologica. 53:261-270. 2016
- Telomere Length and Risk of Myocardial Infarction in a MultiEthnic Population. Journal of the American College of Cardiology. 67:1863-1865. 2016
- New Medications for the Treatment of Diabetes. Diabetes Technology and Therapeutics. 18:S112-S129. 2016
- What accounts for ethnic differences in newborn skinfold thickness comparing South Asians and White Caucasians? Findings from the START and FAMILY Birth Cohorts. International Journal of Obesity. 40:239-244. 2016
- Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study. Scientific Reports. 6:18672. 2016
- Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. Frontiers in Genetics. 7:138. 2016
- Obesity Genes and Risk of Major Depressive Disorder in a Multiethnic Population. Journal of Clinical Psychiatry. 76:e1611-e1618. 2015
- Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. Circulation. 132:2297-2304. 2015
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 373:2247-2257. 2015
- Cognitive Performance at Late Adolescence and the Risk for Impaired Fasting Glucose Among Young Adults. Journal of Clinical Endocrinology and Metabolism (JCEM). 100:4409-4416. 2015
- Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care 2015;38:1067–1074. Diabetes Care. 38:e170-e171. 2015
- Coronary artery disease risk among obese metabolically healthy young men. European Journal of Endocrinology (EJE). 173:305-312. 2015
- Dysglycaemia as a cause of cardiovascular outcomes. Nature Reviews Endocrinology. 11:508-510. 2015
- Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population. Translational Psychiatry. 5:e618-e618. 2015
- Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. Diabetes Care. 38:1558-1566. 2015
- Risk Prediction for Early CKD in Type 2 Diabetes. American Society of Nephrology. Clinical Journal. 10:1371-1379. 2015
- Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. American Journal of Hypertension. 28:995-1009. 2015
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 373:232-242. 2015
- Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies. Journal of Clinical Endocrinology and Metabolism (JCEM). 100:2682-2689. 2015
- Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. American Heart Journal. 170:117-122. 2015
- Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. Human Molecular Genetics. 24:3582-3594. 2015
- Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. European Heart Journal. 36:1454-1462. 2015
- Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochemical Journal. 468:125-132. 2015
- Antenatal exposure to the selective serotonin reuptake inhibitor fluoxetine leads to postnatal metabolic and endocrine changes associated with type 2 diabetes in Wistar rats. Toxicology and Applied Pharmacology. 285:32-40. 2015
- Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care. 38:793-800. 2015
- Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal. 169:631-638.e7. 2015
- Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. Kidney International. 87:784-791. 2015
- Obesity Genes and Risk of Major Depression in a Multiethnic Population. Canadian Journal of Diabetes. 39:S27-S27. 2015
- Effects of intensive glycaemic control on ischaemic heart disease – Authors' reply. The Lancet. 385:1180-1181. 2015
- Association Between Shortened Leukocyte Telomere Length and Cardiometabolic Outcomes. Circulation. Genomic and precision medicine. 8:82-90. 2015
- Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial. Diabetes Care. 38:22-28. 2015
- The Relationship between Intramuscular Adipose Tissue, Functional Mobility, and Strength in Postmenopausal Women with and without Type 2 Diabetes. Journal of Aging Research. 2015:1-9. 2015
- Effect of Hypoglycemia on Brain Structure in People With Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial. Diabetes Care. 37:3279-3285. 2014
- The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care. 37:3244-3252. 2014
- Cognitive Function and the Risk for Diabetes Among Young Men. Diabetes Care. 37:2982-2988. 2014
- Diabetes Risk Among Overweight and Obese Metabolically Healthy Young Adults. Diabetes Care. 37:2989-2995. 2014
- Does genetic heterogeneity account for the divergent risk of type 2 diabetes in South Asian and white European populations?. Diabetologia. 57:2270-2281. 2014
- Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. The Lancet. 384:1936-1941. 2014
- Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. Diabetologia. 57:2030-2037. 2014
- Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. The Lancet Diabetes and Endocrinology. 2:843-851. 2014
- Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT)—Results of a Randomized Controlled Pilot Trial. Canadian Journal of Diabetes. 38:S50-S50. 2014
- Response to Suissa and Azoulay. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366. Diabetes Care. 37:e217-e217. 2014
- Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366. Diabetes Care. 37:e223-e223. 2014
- White blood cell subtypes, insulin resistance and β‐cell dysfunction in high‐risk individuals – the PROMISE cohort. Clinical Endocrinology. 81:536-541. 2014
- Association of cyclooxygenase-2 genetic variant with cardiovascular disease. European Heart Journal. 35:2242-2248. 2014
-
Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub‐study of the
DREAM trial. Diabetic Medicine. 31:1086-1092. 2014 - Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia. 57:1325-1331. 2014
- Cost implications of the use of basal insulin glargine in people with early dysglycemia: The ORIGIN trial. Journal of Diabetes and its Complications. 28:553-558. 2014
- Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. The Lancet Diabetes and Endocrinology. 2:562-572. 2014
- P3‐091: PLASMA AMYLIN LEVELS ARE ASSOCIATED WITH BRAIN STRUCTURE AMONG INDIVIDUALS WITH TYPE‐2 DIABETES. Alzheimer's and Dementia. 10:p661-p661. 2014
- Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. American Heart Journal. 168:23-29.e2. 2014
- Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: A subanalysis of the ORIGIN trial. International Journal of Cardiology. 174:458-461. 2014
- Evaluating the Feasibility and Impact of an Internet-Based Lifestyle Management Program in a Diabetes Care Setting. Diabetes Technology and Therapeutics. 16:358-362. 2014
- Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. Diabetes Care. 37:1721-1728. 2014
- The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care. 37:1360-1366. 2014
-
Prospective association of 25(
OH )D with metabolic syndrome. Clinical Endocrinology. 80:502-507. 2014 - Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI. Diabetologia. 57:738-745. 2014
- Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels. JAMA Internal Medicine. 174:324-324. 2014
- Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study. Diabetes Care. 37:604-610. 2014
- Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial. Diabetes Care. 37:634-643. 2014
- Myocardial Injury after Noncardiac Surgery. Anesthesiology. 120:564-578. 2014
- Metabolic effects of telmisartan in subjects with abdominal obesity: A prospective randomized controlled trial. Blood Pressure. 23:54-60. 2014
- Willingness to take drugs to prevent serious chronic diseases (自愿服用药物以预防严重的慢性疾病). Journal of Diabetes. 6:76-80. 2014
- Writing science that your colleagues can read. Journal of Diabetes and its Complications. 28:4-5. 2014
- Can community retail pharmacist and diabetes expert support facilitate insulin initiation by family physicians? Results of the AIM@GP randomized controlled trial. BMC Health Services Research. 13:71. 2013
- Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: a two year longitudinal study. BMC Musculoskeletal Disorders. 14:114. 2013
- Erratum: The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. Molecular Psychiatry. 18:1324-1324. 2013
- The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. Molecular Psychiatry. 18:1281-1286. 2013
- Short Leg Length, a Marker of Early Childhood Deprivation, Is Associated With Metabolic Disorders Underlying Type 2 Diabetes. Diabetes Care. 36:3599-3606. 2013
- Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. European Heart Journal. 34:3137-3144. 2013
- Association of Depression With Accelerated Cognitive Decline Among Patients With Type 2 Diabetes in the ACCORD-MIND Trial. JAMA psychiatry. 70:1041-1041. 2013
- Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care. 36:2915-2922. 2013
- Postnatal Metabolic and Reproductive Consequences of Fetal and Neonatal Exposure to the Smoking Cessation Drug Bupropion. Reproductive Sciences. 20:1156-1161. 2013
- Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922. Diabetes Care. 36:e181-e181. 2013
- Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. The Lancet Diabetes and Endocrinology. 1:71-78. 2013
- Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events. Diabetes Care. 36:2466-2474. 2013
- Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population. Diabetes Care. 36:2836-2842. 2013
- Setting the record straight on TIDE: a lost opportunity for patients with diabetes. Diabetologia. 56:1884-1887. 2013
- Rosiglitazone and Cardiovascular Outcomes. Circulation. 128:777-779. 2013
- Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal. 34:1966-1966. 2013
- Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial. Diabetes Care. 36:2162-2168. 2013
- Do Lifestyle Changes Reduce Serious Outcomes in Diabetes?. New England Journal of Medicine. 369:189-190. 2013
- Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial. Diabetes Care. 36:1266-1271. 2013
- Hyperglycaemia is associated with impaired vasa vasorum neovascularization and accelerated atherosclerosis in apolipoprotein-E deficient mice. Atherosclerosis. 227:250-258. 2013
- Dual inhibition of the renin–angiotensin system in high-risk diabetes and risk for stroke and other outcomes. Journal of Hypertension. 31:414-421. 2013
- Causal Relationship between Adiponectin and Metabolic Traits: A Mendelian Randomization Study in a Multiethnic Population. PLoS ONE. 8:e66808-e66808. 2013
- Increased cardiovascular risk after pre‐eclampsia in women with dysglycaemia. Diabetic Medicine. 30:e1-e7. 2013
- Impact of a computerized system for evidence-based diabetes care on completeness of records: a before–after study. BMC Medical Informatics and Decision Making. 12:63. 2012
- Basal Insulin and Cardiovascular and Other Outcomes. New England Journal of Medicine. 367:1761-1764. 2012
- Basal insulin and cardiovascular and other outcomes.. New England Journal of Medicine. 367:1763. 2012
- Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respiratory Medicine. 106:1487-1493. 2012
- Changes in Alanine Transaminase and Waist to Hip Ratio as Predictors of Regression to Normoglycemia and AUCglucose0-120min in Adult Patients with Prediabetes. Canadian Journal of Diabetes. 36:S12-S12. 2012
- Does a Patient-managed (PAT) Insulin Intensification Strategy with Insulin Glargine (iGla) and Insulin Glulisine (iGlu) Provide Similar Glycemic Control as Healthcare Professional-managed (HCP) Strategy? Results of the START Study. Canadian Journal of Diabetes. 36:S12-S13. 2012
- 030 Is Accelerated Atherosclerosis a Microvascular Complication of Diabetes?. Canadian Journal of Cardiology. 28:S95-S96. 2012
- Maternal antioxidants prevent β‐cell apoptosis and promote formation of dual hormone‐expressing endocrine cells in male offspring following fetal and neonatal nicotine exposure. Journal of Diabetes. 4:297-306. 2012
- Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. European Journal of Preventive Cardiology (EJPC). 19:755-764. 2012
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine. 367:319-328. 2012
- n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine. 367:309-318. 2012
- Error in Viewpoint in: Statin Therapy for Healthy Men Identified as ‘Increased Risk,’. Journal of the American Medical Association (JAMA). 307:2590-2590. 2012
- Association Between Postoperative Troponin Levels and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. Journal of the American Medical Association (JAMA). 307:2295-2295. 2012
- Is regression to normoglycaemia clinically important?. The Lancet. 379:2216-2218. 2012
- Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. International Journal of Clinical Practice. 66:457-464. 2012
- Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes. Diabetes Care. 35:787-793. 2012
- Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes. Diabetes Care. 35:749-753. 2012
- Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International. 81:586-594. 2012
- Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history). International Journal of Cardiovascular Imaging. 28:455-465. 2012
- Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study. Cardiovascular Revascularization Medicine. 13:95-100. 2012
- Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. European Heart Journal. 33:505-514. 2012
- Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia. 55:36-45. 2012
- Glycemic Index Predicts Individual Glucose Responses after Self-Selected Breakfasts in Free-Living, Abdominally Obese Adults. Journal of Nutrition. 142:27-32. 2012
- Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit. Diabetes Care. 35:19-24. 2012
- Canadian-led capacity-building in biostatistics and methodology in cardiovascular and diabetes trials: the CANNeCTIN Biostatistics and Methodological Innovation Working Group. Trials. 12:48. 2011
- Computerized clinical decision support systems for chronic disease management: A decision-maker-researcher partnership systematic review. Implementation Science. 6:92. 2011
- Establishing a relationship between prolactin and altered fatty acid β-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. BMC Cancer. 11:56. 2011
- Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology. 10:969-977. 2011
- Prospective Associations of Vitamin D With β-Cell Function and Glycemia. Diabetes. 60:2947-2953. 2011
- Shared Electronic Vascular Risk Decision Support in Primary Care. JAMA Internal Medicine. 171:1736-1736. 2011
- Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population. Journal of Diabetes. 3:232-237. 2011
- A community-based approach for the self-management of diabetes. International Diabetes Nursing. 8:54-59. 2011
- Effect of Computer-Generated Tailored Feedback on Glycemic Control in People With Diabetes in the Community. Diabetes Care. 34:1794-1798. 2011
- Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Quality of Life Research. 20:939-943. 2011
- Intensive Glucose Lowering and Cardiovascular Outcomes REPLY. New England Journal of Medicine. 364:2264-2264. 2011
- Long-Acting Risperidone and Oral Antipsychotics in Schizophrenia. New England Journal of Medicine. 364:2264-2266. 2011
- Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal. Diabetes Care. 34:1265-1269. 2011
- Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. New England Journal of Medicine. 364:818-828. 2011
- Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth. Journal of Diabetes. 3:74-81. 2011
- Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. European Heart Journal. 32:581-589. 2011
- Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia. 54:487-495. 2011
- Dysglycaemia, dyslipidaemia and hypertension: risk factors primarily focused on the disease or risk estimates primarily focused on the patient?. Diabetologia. 54:230-232. 2011
- Serious Cardiovascular Outcomes in Diabetes. Circulation. 123:342-348. 2011
- Adipocyte Hypertrophy, Fatty Liver and Metabolic Risk Factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). PLoS ONE. 6:e22112-e22112. 2011
- Association of 25(OH)D and PTH with Metabolic Syndrome and Its Traditional and Nontraditional Components. Journal of Clinical Endocrinology and Metabolism (JCEM). 96:168-175. 2011
- Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes (vol 33, pg 1379, 2010). Diabetes Care. 34:247-247. 2011
- Errata. Diabetes Care. 34:247-247. 2011
- Association of Hematological Parameters with Insulin Resistance and beta-Cell Dysfunction in Nondiabetic Subjects (vol 94, pg 3824, 2009). Journal of Clinical Endocrinology and Metabolism (JCEM). 95:5465-5465. 2010
- Association of hematological parameters with insulin resistance and β-cell dysfunction in nondiabetic subjects (Journal of Clinical Endocrinology and Metabolism (2009) 94, (3824-3832)). Journal of Clinical Endocrinology and Metabolism (JCEM). 95:5465. 2010
- Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia. 53:2509-2517. 2010
- Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: Methods of a decision-maker-researcher partnership systematic review. Implementation Science. 5:12. 2010
- Low-Dose Combination Therapy With Rosiglitazone And Metformin to Prevent Type 2 Diabetes Mellitus (CANOE Trial): A Double-Blind Randomized Controlled Study. Obstetrical and Gynecological Survey. 65:771-772. 2010
- Macular Edema and Thiazolidinediones—Reply. JAMA ophthalmology. 128:1631-1631. 2010
- Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetic Medicine. 27:1226-1232. 2010
- Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Diabetes Care. 33:2250-2253. 2010
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. The Lancet. 376:419-430. 2010
- Long-Term Consequences of Fetal and Neonatal Nicotine Exposure: A Critical Review. Toxicological Sciences. 116:364-374. 2010
- The Effect of Oral Antidiabetic Agents on A1C Levels. Diabetes Care. 33:1859-1864. 2010
- Response to Letter Regarding Article, “Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction”. Circulation. 122:E397-E397. 2010
- Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine. 363:233-244. 2010
- Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. Diabetologia. 53:1322-1330. 2010
- Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: Implications for the evaluation of antidiabetic drugs. American Heart Journal. 160:1-2. 2010
- Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care. 33:1578-1584. 2010
- Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance. Diabetes Care. 33:1629-1634. 2010
- Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance. Diabetes Care. 33:1629-1634. 2010
- Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. The Lancet. 376:103-111. 2010
- A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs. Diabetes Care. 33:1176-1178. 2010
- Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?. Value in Health. 13:487-494. 2010
- Association of Vitamin D With Insulin Resistance and β-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes. Diabetes Care. 33:1379-1381. 2010
- Kidney Disease After Preeclampsia: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases. 55:1026-1039. 2010
- More insights on the dysglycaemia–cardiovascular connection. The Lancet. 375:2195-2196. 2010
- Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Canadian Journal of Cardiology. 26:297-302. 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (vol 362, pg 1563, 2010). New England Journal of Medicine. 362:1748-1748. 2010
- Metabolic Syndrome and Risk of Acute Myocardial Infarction. Journal of the American College of Cardiology. 55:2390-2398. 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine. 362:1563-1574. 2010
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine. 362:1575-1585. 2010
- Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis. Endocrine. 37:303-311. 2010
- Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation. 121:1176-1187. 2010
- Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Diabetes Care. 33:608-613. 2010
- Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes. JAMA ophthalmology. 128:312-312. 2010
- Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers?. Journal of the American Medical Association (JAMA). 303:446-446. 2010
- Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabetic Medicine. 27:175-180. 2010
- The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. The BMJ. 340:b5444-b5444. 2010
- Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction. Circulation. 120:2429-2437. 2009
- Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 52:2288-2298. 2009
- Association of Hematological Parameters with Insulin Resistance and β-Cell Dysfunction in Nondiabetic Subjects. Journal of Clinical Endocrinology and Metabolism (JCEM). 94:3824-3832. 2009
- Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. Clinical Trials. 6:416-429. 2009
- Effects of rosiglitazone on ovarian function and fertility in animals with reduced fertility following fetal and neonatal exposure to nicotine. Endocrine. 36:281-290. 2009
- Albuminuria in chronic heart failure: prevalence and prognostic importance. The Lancet. 374:543-550. 2009
- Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. CANADIAN MEDICAL ASSOCIATION JOURNAL. 181:37-44. 2009
- Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. Journal of Lipid Research. 50:1487-1496. 2009
- Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Journal of the American College of Cardiology. 53:2028-2035. 2009
- Is it possible to reduce cardiovascular risk with glucose-lowering approaches?. Nature Reviews Endocrinology. 5:270-275. 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 32:e58-e58. 2009
- Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care. 32:915-920. 2009
- Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. American Heart Journal. 157:763-770. 2009
- Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET/TRANSCEND Research Programme. Diabetes Research and Clinical Practice. 83:387-393. 2009
- Dysglycemia and Cardiovascular Risk in the General Population. Circulation. 119:773-775. 2009
- Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors. Diabetes Care. 32:221-226. 2009
- The effect of partial meal replacement therapy on weight loss and glycaemic control in obese individuals with type 2 diabetes. Canadian Journal of Diabetes. 33:269-269. 2009
- a meta-analysis of the effect of oral antidiabetic agents on A1c levels at 12 weeks. Canadian Journal of Diabetes. 33:246-247. 2009
- Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics. American Heart Journal. 156:1074-1079. 2008
- Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. Diabetes and Vascular Disease Research. 5:276-284. 2008
- Dr. Byington and colleagues reply. New England Journal of Medicine. 359:1520-1521. 2008
- Intensive glucose control in type 2 diabetes - Reply. New England Journal of Medicine. 359:1520-1521. 2008
- Rosiglitazone prevents diabetes by increasing beta‐cell mass in an animal model of type 2 diabetes characterized by reduced beta‐cell mass at birth. Diabetes, Obesity and Metabolism. 10:763-771. 2008
- The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure. JAMA Internal Medicine. 168:1699-1699. 2008
- Dysglycemia and a History of Reproductive Risk Factors. Diabetes Care. 31:1635-1638. 2008
- Relationship of epicardial fat thickness and fasting glucose. International Journal of Cardiology. 128:424-426. 2008
- Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 358:2545-2559. 2008
- Increased Pancreatic Beta-Cell Apoptosis following Fetal and Neonatal Exposure to Nicotine Is Mediated via the Mitochondria. Toxicological Sciences. 103:362-370. 2008
- Maternal nicotine exposure increases oxidative stress in the offspring. Free Radical Biology and Medicine. 44:1919-1925. 2008
- Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Diabetes Care. 31:1007-1014. 2008
- Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial.. Canadian Family Physician. 54:550-558. 2008
- A systematic review of the effect of oral antidiabetic agents on A1C levels.. Canadian Journal of Diabetes. 32:328-328. 2008
- Assessing the Willingness of Young and Healthy People to take Preventive Medication for Chronic Diseases.. Canadian Journal of Diabetes. 32:320-320. 2008
- Fetal and Neonatal Nicotine Exposure in Wistar Rats Causes Progressive Pancreatic Mitochondrial Damage and Beta Cell Dysfunction. PLoS ONE. 3:e3371-e3371. 2008
- Glycemia Management in Family Practice in Canada - Preliminary Results of a Chart Audit from AIM@GP. Canadian Journal of Diabetes. 32:327-327. 2008
- Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). American Heart Journal. 155:26.e1-26.e13. 2008
- Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies. Diabetes Research and Clinical Practice. 78:305-312. 2007
- Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diabetes Research and Clinical Practice. 78:392-397. 2007
- Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?. Nature Reviews Endocrinology. 3:798-799. 2007
- The effects of exercise training on insulin resistance in patients with coronary artery disease. European Journal of Preventive Cardiology (EJPC). 14:803-808. 2007
- A Family-based Intervention to Promote Healthy Lifestyles in an Aboriginal Community in Canada. Canadian Journal of Public Health. 98:447-452. 2007
- Dysglycemia in a community sample of people treated for schizophrenia: The Diabetes in Schizophrenia in Central-south Ontario (DiSCO) study. Schizophrenia Research. 96:215-222. 2007
- Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study. Diabetes Research and Clinical Practice. 78:254-258. 2007
- Abstract 3631: Elevated In-hospital Glucose Level, and not Known History of Diabetes Mellitus, Predicts 30-day Mortality Following Acute ST-elevation Myocardial Infarction. Circulation. 116. 2007
- Transgenerational effects of fetal and neonatal exposure to nicotine. Endocrine. 31:254-259. 2007
- Fetal and neonatal nicotine exposure and postnatal glucose homeostasis: identifying critical windows of exposure. Journal of Endocrinology. 194:171-178. 2007
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods. American Journal of Cardiology. 99:S21-S33. 2007
- Glycemia Treatment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. American Journal of Cardiology. 99:S34-S43. 2007
- Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. American Journal of Cardiology. 99:S4-S20. 2007
- Point: If it is important to prevent type 2 diabetes, it is important to consider all proven therapies within a comprehensive approach. Journal of Cardiopulmonary Rehabilitation and Prevention. 27:189-189. 2007
- Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk. Circulation. 115:1371-1375. 2007
- A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events. Diabetes Care. 30:389-394. 2007
- Effect of ramipril on the incidence of diabetes - Reply. New England Journal of Medicine. 356:523-524. 2007
- Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach. Diabetes Care. 30:432-434. 2007
- The authors reply [6]. New England Journal of Medicine. 356:523-524. 2007
- Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. Circulation. 115:114-126. 2007
- "I take what I think works for me": a qualitative study to explore patient perception of diabetes treatment benefits and risks.. Journal of Population Therapeutics and Clinical Pharmacology. 14:e251-e259. 2007
- Diabetes and cardiovascular disease: explaining the relationship.. Reviews in Cardiovascular Medicine. 8:145-153. 2007
- Erratum. Clinical Chemistry and Laboratory Medicine. 45:1570. 2007
- Low Socioeconomic Status and Increased Risk of Severe Hypoglycemia in Type 1 Diabetes: A Systematic Literature Review. Canadian Journal of Diabetes. 31:233-241. 2007
- Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. Diabetes Care. 30:162-172. 2007
- Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. Clinical Chemistry and Laboratory Medicine. 45:1180-1185. 2007
- Rosiglitazone delays the development of diabetes mellitus (DREAM trial). Cleveland Clinic Journal of Medicine. 74:64-64. 2007
- The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes. Diabetes Care. 30:188-189. 2007
- Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. American Journal of Kidney Diseases. 48:889-896. 2006
- The DREAM trial – Authors' reply. The Lancet. 368:2050-2051. 2006
- Effect of Ramipril on the Incidence of Diabetes. New England Journal of Medicine. 355:1551-1562. 2006
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet. 368:1096-1105. 2006
- Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes, Obesity and Metabolism. 8:531-537. 2006
- Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes, Obesity and Metabolism. 8:531-537. 2006
- Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 114:201-208. 2006
- A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose‐lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabetic Medicine. 23:736-742. 2006
- Diabetes susceptibility. CANADIAN MEDICAL ASSOCIATION JOURNAL. 174:1598-1598. 2006
- Diabetes susceptibility - Response. CANADIAN MEDICAL ASSOCIATION JOURNAL. 174:1598-1598. 2006
- Intensive insulin therapy reduced cardiovascular disease in type 1 diabetes. ACP journal club. 144:63-63. 2006
- Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?. CANADIAN MEDICAL ASSOCIATION JOURNAL. 174:1090-1091. 2006
- Reply to comment on: Gerstein HC, Pogue J, Mann JFE et al. (2005) The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48:1749–1755. Diabetologia. 49:613-614. 2006
- Why don't pigs get diabetes? Explanations for variations in diabetes susceptibility in human populations living in a diabetogenic environment. CANADIAN MEDICAL ASSOCIATION JOURNAL. 174:25-26. 2006
- Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia. 48:2460-2469. 2005
- Fetal and neonatal exposure to nicotine in Wistar rats results in increased beta cell apoptosis at birth and postnatal endocrine and metabolic changes associated with type 2 diabetes. Diabetologia. 48:2661-2666. 2005
- The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 48:1749-1755. 2005
- Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose.. Evidence report/technology assessment (Summary). 1-11. 2005
- Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. Circulation. 112:48-53. 2005
- Use of Inhaled Insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects. Diabetes Care. 28:1630-1635. 2005
- Insulin Therapy in People Who Have Dysglycemia and Type 2 Diabetes Mellitus: Can It Offer Both Cardiovascular Protection and Beta-Cell Preservation?. Endocrinology and Metabolism Clinics of North America. 34:137-154. 2005
- Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE Study. Clinical Nephrology. 63:181-187. 2005
- The Burden of Treatment Failure in Type 2 Diabetes. Diabetes Care. 28:761-762. 2005
- Glycemia and Risk for Cardiovascular Disease. ACP journal club. 142:227-227. 2005
- Glycemia and Risk for Cardiovascular Disease. ACP journal club. 142:227-227. 2005
- Individualized electronic decision support and reminders can improve diabetes care in the community.. Proceedings - AMIA . Annual Symposium. AMIA Symposium. 2005:982. 2005
- The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences. Scandinavian Journal of Clinical and Laboratory Investigation. 65:143-156. 2005
- Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney International, Supplement. 66:S59-S62. 2004
- Pre‐prandial vs. post‐prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet‐treated or metformin‐treated Type 2 diabetes: a randomized controlled clinical trial. Diabetic Medicine. 21:1200-1203. 2004
- The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes. Diabetes Care. 27:2767-2767. 2004
- Glycosylated Hemoglobin: Finally Ready for Prime Time as a Cardiovascular Risk Factor. ACP journal club. 141:475-475. 2004
- Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 47:1519-1527. 2004
- A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism (JCEM). 89:3668-3676. 2004
- Foot ulcers and amputations in diabetes.. Clinical Evidence. 743-752. 2004
- Patients on Appropriate T4Replacement Are as Content as They Would Be on Any Thyroid Hormone. Journal of Clinical Endocrinology and Metabolism (JCEM). 89:2507-2507. 2004
- Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. Kidney International. 65:1375-1380. 2004
- Authors’ Response: Dosage Recommendations for Combination Regimen of Thyroxine and 3,5,3′-Triiodothyronine. Journal of Clinical Endocrinology and Metabolism (JCEM). 89:1487-1487. 2004
- Dosage Recommendations for Combination Regimen of Thyroxine and 3,5,3′-Triiodothyronine. Journal of Clinical Endocrinology and Metabolism (JCEM). 89:1486-1487. 2004
- Thyroid function screening following radiation therapy for cancers of the head and neck: A survey of Canadian practice patterns. Current Oncology. 11:68-71. 2004
- Foot ulcers and amputations in diabetes.. Clinical Evidence. 657-666. 2003
- Enalapril reduced the risk for new-onset diabetes in left ventricular dysfunction. ACP journal club. 139:68-68. 2003
- Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity.. Canadian Journal of Cardiology. 19:1387-1391. 2003
- Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: Results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. American Journal of Kidney Diseases. 42:936-942. 2003
- Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. American Journal of Kidney Diseases. 42:936-942. 2003
- Does a Combination Regimen of Thyroxine (T4) and 3,5,3′-Triiodothyronine Improve Depressive Symptoms Better Than T4Alone in Patients with Hypothyroidism? Results of a Double-Blind, Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism (JCEM). 88:4551-4555. 2003
- Reducing publication bias of clinical trials by emphasizing methodological rigour. Canadian Journal of Diabetes. 27:126-127. 2003
- Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease. Circulation. 108:420-425. 2003
- New Trial Data on Prevention: Potassium and CV Risk in Hope. PACE - Pacing and Clinical Electrophysiology. 26:1565-1565. 2003
- Cardiovascular risk in patients with mild renal insufficiency. Kidney International, Supplement. 63:S192-S196. 2003
- Development of Renal Disease in People at High Cardiovascular Risk. Journal of the American Society of Nephrology. 14:641-647. 2003
- Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic Population. Diabetes Care. 26:290-296. 2003
- A disturbed glucose metabolic state (dysglycaemia) is a key risk factor for cardiovascular events. European Heart Journal, Supplement. 5:B1-B2. 2003
- Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Research and Clinical Practice. 59:37-42. 2003
- Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. European Heart Journal, Supplement. 5:A43-A48. 2003
- The Relationship Between Dysglycemia and Atherosclerosis in South Asian, Chinese, and European Individuals in Canada. Diabetes Care. 26:144-149. 2003
- Foot ulcers and amputations in diabetes.. Clinical Evidence. 569-577. 2002
- Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes. Diabetes Care. 25:1919-1927. 2002
- Epidemiologic analyses of risk factors, risk indicators, risk markers, and causal factors. Endocrinology and Metabolism Clinics of North America. 31:537-551. 2002
- Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes/Metabolism Research and Reviews. 18:S82-S85. 2002
- The Economic Cost of Diabetes in Canada, 1998. Diabetes Care. 25:1303-1307. 2002
- Foot ulcers and amputations in diabetes.. Clinical Evidence. 521-528. 2002
- Cardiovascular Outcomes and Renal Disease. ACP journal club. 136:634-634. 2002
- Cardiovascular Outcomes and Renal Disease. ACP journal club. 136:633-633. 2002
- The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial. Diabetes Research and Clinical Practice. 55:209-219. 2002
- Cardiovascular Risk in Patients with Early Renal Insufficiency. American Journal of Cardiovascular Drugs. 2:157-162. 2002
- Dysglycemia: A Key Cardiovascular Risk Factor. Seminars in Thrombosis and Hemostasis. 2:165-174. 2002
- The value of large, robust trials: the HOPE study. Practical Diabetes. 19:29-30. 2002
- Fasting Versus Postload Glucose Levels. Diabetes Care. 24:1855-1857. 2001
- Ramipril and the Development of Diabetes. Journal of the American Medical Association (JAMA). 286:1882-1882. 2001
- Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). The Lancet. 358:1147-1153. 2001
- Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients. Stroke. 32:2426-2432. 2001
- Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. ACC Cardiosource Review Journal. 10:25-25. 2001
- Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals. Journal of the American Medical Association (JAMA). 286:421-421. 2001
- Fußgeschwüre bei Diabetes. VASA - Journal of Vascular Medicine. 30:233-237. 2001
- Reducing the Risk of Cardiovascular Complications in the Long-Term Care Setting. Journal of the American Medical Directors Association. 2:H13-H16. 2001
- Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial. ACP journal club. 134:629-629. 2001
- Albuminuria y riesgo de eventos cardiovasculares, mortalidad cardiovascular e insuficiencia cardíaca en sujetos diabéticos y no diabéticos. Hipertension y Riesgo Vascular. 18:452-453. 2001
- Diabetes and the HOPE study: implications for macrovascular and microvascular disease.. International Journal of Clinical Practice, Supplement. 8-12. 2001
- Diabetic foot ulcers. VASA - Journal of Vascular Medicine. 30:233-237. 2001
- The Plasma Glucose Level - A Continuous Risk Factor for Vascular Disease in Both Diabetic and Non-Diabetic People. Advances in Experimental Medicine and Biology. 498:35-39. 2001
- CVD in patients with diabetes. Patient Care. 34:50-72. 2000
- Miglitol, an α-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. Progress in Food and Nutrition Science. 20:1447-1456. 2000
- Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction. Circulation. 102:1014-1019. 2000
- Cardiovascular and metabolic benefits of ACE inhibition: moving beyond blood pressure reduction.. Diabetes Care. 23:882-883. 2000
- Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). The Lancet. 356:279-284. 2000
- Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators.. Diabetes Care. 23 Suppl 2:B35-B39. 2000
- The HOPE study and diabetes. The Lancet. 355:1183-1184. 2000
- The HOPE study and diabetes. The Lancet. 355:1181-1181. 2000
- Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction.. Diabetes Care. 23:377-380. 2000
- Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. The Lancet. 355:773-778. 2000
- Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE).. Indian Heart Journal. 52:S35-S43. 2000
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet. 355:253-259. 2000
- Perceived exertion with glucose ingestion in adolescent males with IDDM. Medicine & Science in Sports & Exercise. 32:167-167. 2000
- Preventing cardiovascular diseases in people with diabetes.. Canadian Journal of Cardiology. 15 Suppl G:65G-68G. 1999
- A controlled evaluation of a national continuing medical education programme designed to improve family physicians’ implementation of diabetes‐specific clinical practice guidelines. Diabetic Medicine. 16:964-969. 1999
- 35th Annual Meeting of the European Association for the Study of Diabetes. Diabetologia. 42:A1-A330. 1999
- Review: Glucose levels are associated with cardiovascular risk in persons without diabetes mellitus. Evidence-Based Medicine. 4:127. 1999
- Preventive medicine in people at high risk for chronic disease: the value of identifying and treating diabetes.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 160:1593-1595. 1999
- Preventive medicine in people at high risk for chronic disease: the value of identifying and treating diabetes. Rebuttal to Marshall. CANADIAN MEDICAL ASSOCIATION JOURNAL. 160:1596-1596. 1999
- Is glucose a continuous risk factor for cardiovascular mortality?. Diabetes Care. 22:659-660. 1999
- Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis.. Diabetes Care. 22 Suppl 2:B35-B39. 1999
- Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. Journal of the American College of Cardiology. 33:612-619. 1999
- TREATMENT. Evidence-based Cardiovascular Medicine. 3:21-25. 1999
- Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Canadian Journal of Physiology and Pharmacology. 77:118-123. 1999
- Preventive medicine in a diabetes clinic: an opportunity to make a difference. The Lancet. 353:606-608. 1999
- The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.. Diabetes Care. 22:233-240. 1999
- Antihypertensive therapy in patients with type 2 diabetes mellitus: focus on nephropathy.. Advances in nephrology from the Necker Hospital. 29:241-255. 1999
- Intensive blood glucose control reduced type 2 diabetes mellitus-related end points. ACP journal club. 130:2-2. 1999
- Metformin reduced diabetes-related end points and all-cause mortality in overweight patients with type 2 diabetes. ACP journal club. 130:3-3. 1999
- Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors. Clinical and Experimental Hypertension. 21:835-845. 1999
- Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene.. Clinical and Investigative Medicine. 21:251-257. 1998
- The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators.. Canadian Journal of Cardiology. 14:1349-1357. 1998
- The study of health assessment and risk in ethnic groups (SHARE): Rationale and design. Canadian Journal of Cardiology. 14:1349-1357. 1998
- Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.. Journal of Clinical Endocrinology and Metabolism (JCEM). 83:3169-3176. 1998
- Dysglycaemia: a cardiovascular risk factor. Diabetes Research and Clinical Practice. 40:S9-S14. 1998
- Lisinopril inhibited the progression of renal albumin excretion in patients with insulin-dependent diabetes mellitus.. Evidence-based Cardiovascular Medicine. 2:23-24. 1998
- Ramipril slowed the decline in renal function among patients with nephropathy and proteinuria not due to insulin-dependent diabetes mellitus. Evidence-based Cardiovascular Medicine. 2:23-24. 1998
- 1998 clinical practice guidelines for the management of diabetes in Canada. CANADIAN MEDICAL ASSOCIATION JOURNAL. 159:S1-S29. 1998
- 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 159 Suppl 8:S1-29. 1998
- Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. Evidence-based Cardiovascular Medicine. 1:87-88. 1997
- Glucose: a Continuous Risk Factor for Cardiovascular Disease. Diabetic Medicine. 14:S25-S31. 1997
- The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. JAMA Internal Medicine. 157:1413-1418. 1997
- Psychiatric Symptoms, Bone Density and Non-Specific Symptoms in Patients with Mild Hypercalcemia due to Primary Hyperparathyroidism: A Systematic Overview of the Literature.. Endocrine Journal. 44:367-374. 1997
- Does treatment withl-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism?. Journal of General Internal Medicine. 11:744-749. 1996
- Insulin infusion followed by multiple daily insulin injections reduced mortality after Ml in diabetes. Evidence-Based Medicine. 1:41. 1996
- Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study. Diabetes Care. 19:1225-1228. 1996
- Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.. Diabetes Care. 19:1225-1228. 1996
- A New Mutation in the Thyroid Hormone Receptor (TR) β Gene (V458A) in a Family with Resistance to Thyroid Hormone (RTH). Thyroid. 6:311-312. 1996
- Risk factors for acute myocardial infarction in Indians: a case-control study. The Lancet. 348:358-363. 1996
- Dysglycaemia and risk of cardiovascular disease - Reply. The Lancet. 347:1834-1835. 1996
- Dysglycaemia and risk of cardiovascular disease. The Lancet. 347:1833-1835. 1996
- Dysglycaemia and risk of cardiovascular disease. The Lancet. 347:949-950. 1996
- Users' Guides to the Medical Literature. Journal of the American Medical Association (JAMA). 275:554-554. 1996
- The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.. Canadian Journal of Cardiology. 12:127-137. 1996
- Insulin infusion followed by multiple daily insulin injections reduced mortality after MI in diabetes. ACP journal club. 124:1-1. 1996
- The Relationship Between Cow’s Milk Exposure and Type 1 Diabetes. Diabetic Medicine. 13:23-29. 1996
- USERS GUIDES TO THE MEDICAL LITERATURE .9. A METHOD FOR GRADING HEALTH-CARE RECOMMENDATIONS. Journal of the American Medical Association (JAMA). 274:1800-1804. 1995
- Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. Journal of the American Medical Association (JAMA). 274:1800-1804. 1995
- Collaborative cardiovascular clinical trials in Canada. The Canadian Cardiovascular Collaboration.. Canadian Journal of Cardiology. 11:649-657. 1995
- Feasibility and Acceptability of a Proposed Infant Feeding Intervention Trial for the Prevention of Type I Diabetes. Diabetes Care. 18:940-942. 1995
- USERS GUIDES TO THE MEDICAL LITERATURE .7. HOW TO USE A CLINICAL DECISION-ANALYSIS .B. WHAT ARE THE RESULTS AND WILL THEY HELP ME IN CARING FOR MY PATIENTS. Journal of the American Medical Association (JAMA). 273:1610-1613. 1995
- Users' guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? Evidence Based Medicine Working Group. Journal of the American Medical Association (JAMA). 273:1610-1613. 1995
- USERS GUIDES TO THE MEDICAL LITERATURE .6. HOW TO USE AN OVERVIEW. Journal of the American Medical Association (JAMA). 272:1367-1371. 1994
- Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. Journal of the American Medical Association (JAMA). 272:1367-1371. 1994
- Spectrum of quality of life impairment in hypothyroidism. Quality of Life Research. 3:323-327. 1994
- USERS GUIDES TO THE MEDICAL LITERATURE .5. HOW TO USE AN ARTICLE ABOUT PROGNOSIS. Journal of the American Medical Association (JAMA). 272:234-237. 1994
- USERS GUIDES TO THE MEDICAL LITERATURE .4. HOW TO USE AN ARTICLE ABOUT HARM. Journal of the American Medical Association (JAMA). 271:1615-1619. 1994
- USERS GUIDES TO THE MEDICAL LITERATURE .3. HOW TO USE AN ARTICLE ABOUT A DIAGNOSTIC-TEST .B. WHAT ARE THE RESULTS AND WILL THEY HELP ME IN CARING FOR MY PATIENTS. Journal of the American Medical Association (JAMA). 271:703-707. 1994
- Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. Journal of the American Medical Association (JAMA). 271:703-707. 1994
- USERS GUIDES TO THE MEDICAL LITERATURE .3. HOW TO USE AN ARTICLE ABOUT A DIAGNOSTIC-TEST .A. ARE THE RESULTS OF THE STUDY VALID. Journal of the American Medical Association (JAMA). 271:389-391. 1994
- Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. Journal of the American Medical Association (JAMA). 271:389-391. 1994
- USERS GUIDES TO THE MEDICAL LITERATURE .2. HOW TO USE AN ARTICLE ABOUT THERAPY OR PREVENTION .B. WHAT WERE THE RESULTS AND WILL THEY HELP ME IN CARING FOR MY PATIENTS. Journal of the American Medical Association (JAMA). 271:59-63. 1994
- Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. Journal of the American Medical Association (JAMA). 271:59-63. 1994
- Cow's Milk Exposure and Type I Diabetes Mellitus: A critical overview of the clinical literature. Diabetes Care. 17:13-19. 1994
- Screening for postpartum thyroid dysfunction.. Comprehensive Therapy. 20:331-335. 1994
- Development of residency program guidelines for interaction with the pharmaceutical industry. Education Council, Residency Training Programme in Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ont.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 149:405-408. 1993
- Incidence of Postpartum Thyroid Dysfunction in Patients with Type I Diabetes Mellitus. ACP journal club. 118:419-419. 1993
- Exercise in the Prevention of Diabetes Mellitus in Male Physicians. Clinical Journal of Sport Medicine. 3:61-61. 1993
- Evidence-Based Medicine. Journal of the American Medical Association (JAMA). 268:2420-2420. 1992
- RISKS ASSOCIATED WITH TREATING HYPOTHYROIDISM. Canadian Family Physician. 38:1467-1474. 1992
- Risks Associated with Treating Hypothyroidism: Potential hazards of L-thyroxine therapy.. Canadian Family Physician. 38:1467-1474. 1992
- Symptoms of hypoglycemia with human versus porcine insulin. Annals of Internal Medicine. 116:33-34. 1992
- Relapse frequently occurred in Graves disease after treatment. ACP journal club. 115:91-91. 1991
- Intensified insulin increased the risk for serious hypoglycemia and neuroglycopenia in IDDM. ACP journal club. 114:84-84. 1991
- 3-Year effects of intensified insulin on hypoglycemia. Annals of Internal Medicine. 114:84. 1991
- 3-Year effects of intensified insulin on hypoglycemia. Annals of Internal Medicine. 114:84. 1991
- How common is postpartum thyroiditis? A methodologic overview of the literature. JAMA Internal Medicine. 150:1397-1400. 1990
- IMMUNOMODULATORY EFFECT OF THE TREATMENT OF GRAVES’DISEASE ON ANTIGEN‐SPECIFIC MONOCYTE PROCOAGULANT ACTIVITY PRODUCTION. Clinical Endocrinology. 27:321-330. 1987
- The decrease in non-specific suppressor T lymphocytes in female hyperthyroid Graves' disease is secondary to the hyperthyroidism.. Clinical and Investigative Medicine. 10:337-344. 1987
- Separate Induction of MHC and Thyroid Microsomal Antigen (McAg) Expression on Thyroid Cell Monolayers: Enhancement of Lectin-Induced McAg Expression by Interferon-γ*. Journal of Clinical Endocrinology and Metabolism (JCEM). 64:1302-1308. 1987
- Sensitization of T lymphocytes to thyroid antigen in autoimmune thyroid disease as demonstrated by the monocyte procoagulant activity test. Journal of Endocrinological Investigation. 9:471-478. 1986
- Thyrocyte HLA-DR Expression and Interferon-γProduction in Autoimmune Thyroid Disease*. Journal of Clinical Endocrinology and Metabolism (JCEM). 63:695-708. 1986
- AIDS in a patient with hemophilia receiving mainly cryoprecipitate.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 131:45-47. 1984
- Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Yearbook of Paediatric Endocrinology.
-
preprints
- Proteome-wide Mendelian randomization study implicates inflammaging biomarkers in retinal vasculature, cardiometabolic diseases and longevity 2024
- Large and small peripheral arterial disease in persons with type 2 diabetes 2023
- Multi-ancestry genome-wide study in >2.5 million individuals reveals heterogeneity in mechanistic pathways of type 2 diabetes and complications 2023
- Global variation in tests of cognitive and physical function: analysis of six international randomized controlled trials 2023
- Trans-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation 2020
- Clinical benefits and adverse effects of genetically-elevated free testosterone levels: a Mendelian randomization analysis 2019
- Penetrance of polygenic obesity susceptibility loci across the body mass index distribution: an update on scaling effects 2017